Sadeghi N, Khalife S, Mascarella MA, et al. - Among 54 individuals with HPV-positive oropharynx cancer (OPC), researchers conducted this prospective observational study to evaluate the ability of tumor volume reduction on imaging to anticipate pathological response to neoadjuvant chemotherapy. Participants in the study were patients with HPV-positive OPC registered in a clinical trial of neoadjuvant chemotherapy followed by surgery. Study participants had three cycles of induction chemotherapy (cisplatin/docetaxel); prechemotherapy and postchemotherapy imaging have been obtained. Data reported that the complete pathologic response (pCR) rate at primary and nodal sites, respectively, were 72% and 57%. Findings suggested that tumor volume reduction of ≥ 90% following induction chemotherapy anticipated pCR of the primary tumor. Neoadjuvant chemotherapy accompanied by definitive transoral surgery is a new paradigm worth investigating further, and MRI is a reliable modality for assessing preoperative response.